Of note, the AR+ HOXB13–negative GRN in the ARhigh/PSMAlow sample showed robust STEAP1 and STEAP2 expression, suggesting that co–targeting of STEAP and PSMA in AR–positive disease may be an effective strategy to achieve broader tumor cell coverage (4) (Figure 4D). This evidence concerns the gene GRN and neoplasm.